Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in coming weeks.

Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib: Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in… 👈 Read full analysis #Psoriasis #ClinicalTrials #Envudeucitinib #Phase3Trials #Dermatology